In women with inherited bleeding disorders and menorrhagia, adjusted mean PBAC scores were slightly lower with DDAVP than placebo (mean difference 8, 95% CI -15.5 to 31.6), but the difference was not statistically significant (P = 0.51).
In plain wordsIn women with inherited bleeding disorders, menstrual bleeding scores were slightly lower with DDAVP than placebo, but the difference was not statistically significant.
- Peptide
- Desmopressin
- Outcome
- No significant changePBAC score
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Bleeding · Whole body
- Studied dose
- 300 micro g · nasal spray · 2 monthsAs given in this study (human).
Measurements
- Mean PBAC difference
- 8 PBAC score
- adjusted, DDAVP versus placebo
- 95% CI of mean difference
- −15.5 to 31.6 PBAC score
- adjusted, DDAVP versus placebo
- P value
- 0.51
- DDAVP versus placebo
Source sentences
After adjusting for this differences, mean PBAC scores were slightly lower (mean difference 8; 95% confidence interval of - 15.5 to 31.6) in women receiving DDAVP than when receiving placebo, although this difference was not statistically significant (P = 0.51).
3 context sentences(design, population, supporting numbers)
39 women (aged 18-50 years) with menorrhagia were recruited and were randomized to start 2 months' therapy with placebo or DDAVP (300 micro g) spray in a double-blind crossover study.
Twenty-eight and 24 completed first and second period of treatment, respectively.
The main outcome measure was comparison of PBAC scores following DDAVP and placebo treatments.